SLSN SOLESENCE, INC.
Perfumes, Cosmetics & Other Toilet Preparations · Nasdaq · SEC CIK 883107 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.0%
TTM net income YoY364.7%
TTM EPS YoY1,152,921,504,606,847,232.0%
Revenue 3-yr CAGR17.5%
Net income 3-yr CAGR—
Margins
Gross margin31.7%
Operating margin6.0%
Net margin4.5%
FCF margin—
EBITDA margin8.0%
Returns
ROE18.2%
ROA5.8%
ROIC (approx.)25.8%
Asset turnover1.29x
Leverage & solvency
Liabilities / assets62.3%
Debt / equity0.00x
Current ratio1.73x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.72x
Accruals ratio-15.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $62.06M | $52.35M |
| Cost of revenue | $44.98M | $39.30M |
| Gross profit | $17.08M | $13.05M |
| R&D expense | $4.09M | $3.84M |
| SG&A expense | $10.40M | $7.22M |
| Operating income | $2.59M | $2.00M |
| Interest expense | — | $670,000 |
| Pretax income | $2.88M | $1.33M |
| Income tax | $73,000 | $227,000 |
| Net income | $2.81M | $1.10M |
| EBITDA | $3.49M | $2.92M |
| EPS (basic) | 0.04 | 0.02 |
| EPS (diluted) | 0.04 | 0.02 |
| Weighted avg. shares (diluted) | 72.58M | 65.03M |
| Balance sheet | ||
| Cash & equivalents | $1.29M | $1.41M |
| Receivables | $6.84M | $4.87M |
| Inventory | $14.88M | $15.62M |
| Current assets | $25.14M | $24.70M |
| PP&E, net | $14.33M | $12.73M |
| Total assets | $46.42M | $45.35M |
| Current liabilities | $13.93M | $25.77M |
| Total liabilities | $32.42M | $35.06M |
| Shareholders' equity | $14.00M | $10.29M |
| Shares outstanding | 70.61M | 70.10M |
| Cash flow statement | ||
| Operating cash flow | -$8.57M | $1.97M |
| Capital expenditure | — | $4.56M |
| Free cash flow | — | -$2.59M |
| Investing cash flow | -$2.14M | -$4.56M |
| Financing cash flow | $10.59M | $2.27M |
| Depreciation & amortization | $897,000 | $928,000 |
| Stock-based compensation | $575,000 | $725,000 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.